MedTrace Logo

Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge

NCT01260753 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-04-15

No results posted yet for this study

Summary

The purpose of this study is to explore the activity of UR-63325 in a model of allergic rhinitis induced by nasal allergen challenge to known allergic rhinitis patients otherwise healthy.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

UR-63325

UR-63325

DRUG

Fluticasone propionate nasal spray

Fluticasone propionate nasal spray

DRUG

Placebo

Placebo to UR 63325 and fluticasone propionate nasal spray

Sponsors & Collaborators

  • Palau Pharma S.L.U.

    lead INDUSTRY

Principal Investigators

  • Rainard Fuhr, MD · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01260753 on ClinicalTrials.gov